logo-loader
viewAlgernon Pharmaceuticals Inc.

Full interview: Algernon Pharmaceuticals receives ok from South Korea for phase two study of Ifenprodil

Algernon Pharmaceuticals ((CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive in Vancouver with big news the company has received approval from the Ministry of Food and Drug Safety in South Korea, for a Phase 2 COVID-19 clinical study of their repurposed drug Ifenprodil . 

Moreau telling Proactive how this study will be conducted and also where they are as far as Health Canada is concerned.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.255 CAD

CSE:AGN
Market: CSE
Market Cap: $22.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tabula launches new ETF focussing on North American High Yield Credit Market

Tabula Investment Management Limited (LSE: TABS) CEO MJ Lytle joined Steve Darling from Proactive with news the company has started a new ETF that will be exclusively located on the London Stock Exchange under the ticker “TABS”  Lytle telling Proactive that ETF will focus on short exposure...

7 hours, 7 minutes ago

2 min read